Bagzvard: Recent studies have shown that the specific diabetes drug liraglutide may slow the progression of Alzheimer’s disease.
Novo Nordisk Pharma Company’s drug liraglutide is known as a diabetes and obesity drug, but recent studies have shown that liraglutide can slow the progression of Alzheimer’s disease by protecting the brains of patients.
The liraglutide formulation is marketed under the brand names Victoza and Saxenda as a diabetes and obesity drug, respectively.
The study results add to the evidence that obesity and diabetes medications can provide important health benefits beyond weight loss and blood sugar regulation.
The last two years have seen an increase in demand for GLP-1. Experts are studying the potential of Novo Nordisk’s liraglutide drug in patients with chronic conditions ranging from liver disease to sleep apnea.
Leave feedback about this